8.5 C
Glasgow
Tuesday, October 14, 2025
spot_img

More News

Precision Cell Systems acquires BennuBio

Jim Cornall -
Precision Cell Systems (PCS) has acquired BennuBio to enter the 3D cell culture market. The acquisition brings BennuBio's Velocyt imaging...

Blood test for chronic fatigue syndrome unveiled

admin -
Scientists at the University of East Anglia and Oxford Biodynamics have developed a high accuracy blood test to diagnose...

New antibiotic targets IBD

Jim Cornall -
Researchers at McMaster University in Canada and the Massachusetts Institute of Technology (MIT) have made two scientific breakthroughs at...

First gene therapy for rare subtype of Charcot-Marie-Tooth disease clears hurdle

Jim Cornall -
CMT Research Foundation has announced they have funded Elpida Therapeutics to launch manufacturing of a gene therapy drug for...

Positive results from Crohn’s disease trial

Jim Cornall -
Amorphical has announced positive interim results from its ongoing open-label clinical trial evaluating its investigational therapy for the treatment...

Crystalys Therapeutics launches with $205m to take on gout

Jim Cornall -
Crystalys Therapeutics Inc. has launched with a $205m Series A financing to support its mission of addressing the significant...

New radiopharmaceutical preclinical CRO created

Jim Cornall -
CPDC has launched Cadena Research, a new preclinical contract research organisation (CRO) offering specialized support for early-stage drug development...

JV to develop small molecule targeting DNA damage response in glioblastoma

Jim Cornall -
BioLineRx Ltd. and Hemispherian AS have established a joint venture (JV) to develop GLIX1, a first-in-class, oral, small molecule...

Tumour cells exploit damaged tissue in the pancreas

Jim Cornall -
Pancreatic cancer is one of the most aggressive cancer types. A new study from Sweden’s Karolinska Institutet, in collaboration...

Imlifidase successfully meets primary kidney transplantation endpoint

Jim Cornall -
Hansa Biopharma AB has announced positive topline results from the US Phase 3 ConfIdeS trial of imlifidase, evaluating 12-month...

Base to Base biotech podcast 29: Blood pressure and radiopharmaceuticals

Jim Cornall -
This week, we have two interviews again. We talk about treating high blood pressure with CEO of George Medicines,...

METiS launches world’s first AI-driven nano-delivery platform

Jim Cornall -
METiS TechBio has launched NanoForge, the world's first end-to-end AI-driven nano-delivery platform. Chris Lai, co-founder and CEO of METiS, led...

Pfizer set to lower drug costs for American patients

Jim Cornall -
Pfizer Inc. has announced an agreement with the Trump Administration that will ensure U.S. patients pay lower prices for...

Enlarged cancer cell nucleus explained

Jim Cornall -
In tissue biopsies, cancer cells are frequently observed to have nuclei (the cell's genetic information storage) larger than normal....

New drug candidate blocks lung cancer but leaves healthy cells

Jim Cornall -
Researchers have discovered a promising new approach to lung cancer treatment. A small molecule called AVJ16 selectively blocks the cancer-driving...

Haemodialysis treatment sees “transformative” results

Jim Cornall -
Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, has announced...

New immunotherapy targets common cancer mutation

Jim Cornall -
Researchers at the University of Oslo and Oslo University Hospital in Norway have developed a promising new immunotherapy targeting...

Synaffix and Qurient Therapeutics to develop dual-payload ADC

Jim Cornall -
Synaffix B.V. has entered into a licensing agreement with South Korean biopharma company Qurient Co., Ltd. for the development...

Tagomics publishes new approach to genome-wide epigenomic profiling

Jim Cornall -
Tagomics Ltd. has announced the publication of a peer-reviewed study in Cell Reports Methods, underpinning its epigenomic profiling technology,...

Fast-acting actin explains the survival of cancer cells

Jim Cornall -
Researchers of the University of Freiburg Cluster of Excellence CIBSS in Germany have shown an actin scaffold stabilises the...

Phase 2 data for chronic inducible urticaria

Jim Cornall -
Evommune, Inc. has presented additional positive data from its phase 2 trial of EVO756 in adults with chronic inducible...

Deeptech Digest is your guide to what's new in at the cutting edge of science technology. A bit of artificial intelligence, some biotech, and all the news and latests developments in the field. If it's deeptech, it's in Deeptech Digest!

Contact us: jim@deeptechdigest.com

© 2023 Ayr Coastal Media